These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6144620)

  • 1. [Tolerance of nitrefazole in alcoholics with liver disease. A 4-week placebo-controlled double-blind study].
    Feuerlein W; Heesch D; Schmidt L; Werner HP; Bethge H; Görtelmeyer R
    Fortschr Med; 1984 Apr; 102(14):409-13. PubMed ID: 6144620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Capsule metadoxine in the treatment of alcoholic liver disease: a randomized, double-blind, placebo-controlled, multicenter study].
    Mao YM; Zeng MD; Li YM; Wang BY; Shang J; Shi RH; Liu JY; Lu LG; Cao AP
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):213-6. PubMed ID: 19335986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (+)-Cyanidanol-3 for alcoholic liver disease: results of a six-month clinical trial.
    World MJ; Aps EJ; Shaw GK; Thomson AD
    Alcohol Alcohol; 1984; 19(1):23-9. PubMed ID: 6149758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin.
    Hock B; Schwarz M; Domke I; Grunert VP; Wuertemberger M; Schiemann U; Horster S; Limmer C; Stecker G; Soyka M
    Addiction; 2005 Oct; 100(10):1477-86. PubMed ID: 16185209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].
    Fehér J; Deák G; Müzes G; Láng I; Niederland V; Nékám K; Kárteszi M
    Orv Hetil; 1989 Dec; 130(51):2723-7. PubMed ID: 2574842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Uridine diphosphate glucose (UDPG) in the treatment of hepatic disease from chronic alcohol abuse].
    Tarantino G; Morelli L; Califano C
    Riv Eur Sci Med Farmacol; 1990 Apr; 12(2):109-17. PubMed ID: 2080308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Controlled study of the effect of silymarin on alcoholic liver disease].
    Bunout D; Hirsch S; Petermann M; de la Maza MP; Silva G; Kelly M; Ugarte G; Iturriaga H
    Rev Med Chil; 1992 Dec; 120(12):1370-5. PubMed ID: 1343377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma-glutamyltranspeptidase, aspartate aminotransferase, and erythrocyte mean corpuscular volume as indicators of alcohol consumption in liver disease.
    Eriksen J; Olsen PS; Thomsen AC
    Scand J Gastroenterol; 1984 Sep; 19(6):813-9. PubMed ID: 6151242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of treatment with paromomycin on endotoxemia in patients with alcoholic liver disease--a double-blind, placebo-controlled trial.
    Bode C; Schäfer C; Fukui H; Bode JC
    Alcohol Clin Exp Res; 1997 Nov; 21(8):1367-73. PubMed ID: 9394106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study.
    Cadranel JF; Di Martino V; Dorent R; Bernard B; Hoang C; Myara A; Pauwels A; Ghoussoub JJ; Perrin M; Grippon P; Thabut D; Trivin F; Huraux JM; Gandjbakhch I; Opolon P; Lunel F
    Transplantation; 2003 Apr; 75(7):977-82. PubMed ID: 12698083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prediction of histological liver damage in asymptomatic alcoholic patients by means of clinical and laboratory data].
    Iturriaga H; Hirsch S; Bunout D; Díaz M; Kelly M; Silva G; de la Maza MP; Petermann M; Ugarte G
    Rev Med Chil; 1993 Apr; 121(4):369-78. PubMed ID: 7903815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot double-blind treatment trial of memantine for alcohol dependence.
    Evans SM; Levin FR; Brooks DJ; Garawi F
    Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism--preliminary data.
    Soyka M; Sass H
    Alcohol Alcohol Suppl; 1994; 2():531-6. PubMed ID: 8974379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma alcohol dehydrogenase in normal and alcoholic individuals.
    Meier-Tackmann D; Agarwal DP; Goedde HW
    Alcohol Alcohol; 1984; 19(1):7-12. PubMed ID: 6149759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
    Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polysomnography during withdrawal with clomethiazole or placebo in alcohol dependent patients--a double-blind and randomized study.
    Gann H; Feige B; Cloot O; Van Wasen H; Zinzgraf D; Hohagen F; Riemann D
    Pharmacopsychiatry; 2004 Sep; 37(5):228-35. PubMed ID: 15359376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A controlled clinical study on the efficacy and tolerability of stepronin in chronic alcoholic liver diseases].
    De Rensis L; Schianchi L; Assunto A; Antenora G; Allocca F; Bossone V
    Clin Ter; 1990 Nov; 135(3):209-13. PubMed ID: 2150022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study.
    Crosignani A; Budillon G; Cimino L; Del Vecchio Blanco C; Loguercio C; Ideo G; Raimondo G; Stabilini R; Podda M
    Hepatogastroenterology; 1998; 45(23):1624-9. PubMed ID: 9840118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.